Treatment of congenital vascular malformations using sirolimus

Phase 3, open-label, single-arm trial of sirolimus in venous malformation (VM), lymphangioma and vascular malformation, sponsored by Radboud University Medical Center. Primary endpoints: Pain reduction after six months of sirolimus treatment and Required length of sirolimus therapy to achieve and maintain adequate pain reduction. Started Jul 2017; status: completed.